Borson, Soo
Small, Gary W.
O’Brien, Quentin
Morrello, Andrea
Boustani, Malaz
Funding for this research was provided by:
Genentech, Inc. and F. Hoffmann-La Roche
Article History
Received: 12 June 2023
Accepted: 16 October 2023
First Online: 6 November 2023
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Borson (SB) conducts research focused on improving early detection of dementia in health care settings and is supported by grants from the Centers for Disease Control and Prevention and the National Institutes of Health. SB owns the copyright on the Mini-Cog, a cognitive screening tool for dementia detection in primary care. SB co-leads the BOLD Public Health Center of Excellence on Early Detection of Dementia. SB provides technical assistance to health care and public health organizations and is an advisor to multiple pharmaceutical and educational companies (Biogen, Eisai, Lilly, Genentech, and Medscape) seeking to disseminate best practices for dementia detection and care. Dr. Small (GS) is an advisor for Acadia, Biogen, Corium, Genentech, Roche, Handok, Herbalife, Lundbeck, McCormick Science Institute, Otsuka, Reckitt Bencksier Group, and Theravaules. He also has equity in Ceremark Pharma. Dr. Boustani (MB) serves as a chief scientific officer and cofounder of BlueAgilis; and the chief health officer of DigiCARE Realized, Inc. MB has equity interest in Blue Agilis, Inc; DigiCARE Realized, Inc; Preferred Population Health Management LLC; and MyShyft, Inc (previously known as RestUp, LLC). MB serves as an advisory board member for Acadia Pharmaceuticals; Eisai, Inc; Biogen; Lilly, and Genentech. These conflicts have been reviewed by Indiana University and has been appropriately managed to maintain objectivity. Quentin O’Brien and Andrea Morrello are employees of Health & Wellness Partners, LLC, which received payment from Genentech for services rendered. They have no other conflicts of interest to disclos